List of Excipients in Branded Drug NUCYNTA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Stat Rx USA	NUCYNTA	tapentadol hydrochloride	16590-863	ALUMINUM OXIDE
Stat Rx USA	NUCYNTA	tapentadol hydrochloride	16590-863	CELLULOSE, MICROCRYSTALLINE
Stat Rx USA	NUCYNTA	tapentadol hydrochloride	16590-863	CROSCARMELLOSE SODIUM
Stat Rx USA	NUCYNTA	tapentadol hydrochloride	16590-863	LACTOSE MONOHYDRATE
Stat Rx USA	NUCYNTA	tapentadol hydrochloride	16590-863	MAGNESIUM STEARATE
Stat Rx USA	NUCYNTA	tapentadol hydrochloride	16590-863	POLYETHYLENE GLYCOL
Stat Rx USA	NUCYNTA	tapentadol hydrochloride	16590-863	POLYVINYL ALCOHOL

Last updated: August 18, 2026

NUCYNTA’s excipient strategy is commercially relevant because tapentadol is sold in two oral dosage forms with different release requirements: immediate-release NUCYNTA and extended-release NUCYNTA ER. The strongest opportunities are generic or reformulated products that preserve tapentadol exposure while improving manufacturability, tablet robustness, swallowing, packaging, and abuse-deterrence characteristics. Excipients alone do not create an abuse-deterrent claim; the formulation must undergo FDA review and support the applicable labeling.

NUCYNTA Excipient Strategy and Commercial Opportunities

What excipients are used in NUCYNTA immediate-release tablets?

NUCYNTA immediate-release tablets use a conventional compressed-tablet platform. The FDA labeling identifies the core excipients as microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, povidone K30, and magnesium stearate. The film coating contains standard coating materials, including polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and colorants that vary by strength.[1]

Component	Function in NUCYNTA IR
Microcrystalline cellulose	Diluent and compression aid
Lactose monohydrate	Diluent and tablet bulk
Croscarmellose sodium	Superdisintegrant
Povidone K30	Binder
Magnesium stearate	Lubricant
Polyvinyl alcohol	Film-forming coating polymer
Polyethylene glycol	Plasticizer
Talc	Anti-tacking and coating aid
Titanium dioxide and colorants	Opacity and dose-strength identification

The formulation is compatible with standard high-volume generic manufacturing. Its principal commercial vulnerability is that most listed excipients are common, low-cost materials with multiple qualified suppliers. A generic manufacturer therefore has limited ability to differentiate through the excipient list alone.

Which NUCYNTA IR excipients create the main formulation risks?

The main risks are lactose exposure, lubrication sensitivity, disintegration variability, and tablet-coating performance.

Lactose can restrict use by patients with certain excipient sensitivities and creates a potential commercial opening for lactose-free tapentadol tablets. That opportunity is limited because lactose intolerance generally does not preclude use of pharmaceutical lactose, and a lactose-free claim must be supported by manufacturing controls.

Croscarmellose sodium and magnesium stearate require process control. Excessive magnesium stearate or over-lubrication can slow wetting and dissolution. Changes in particle size, blending time, compression force, or lubricant concentration can alter disintegration and dissolution even when the nominal excipient composition remains similar.

Povidone K30 supports tablet hardness and processability. A generic manufacturer could substitute another binder, such as copovidone or pregelatinized starch, but the change would require comparative dissolution and bioequivalence support.

What excipients are used in NUCYNTA ER?

NUCYNTA ER uses a hydrophilic matrix extended-release design. The FDA label identifies hypromellose, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate in the tablet core. The coating uses polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and strength-specific colorants.[2]

Component	Function in NUCYNTA ER
Hypromellose	Hydrophilic matrix former controlling drug release
Microcrystalline cellulose	Diluent and compression aid
Colloidal silicon dioxide	Glidant and flow aid
Magnesium stearate	Lubricant
Polyvinyl alcohol	Film-forming coating polymer
Polyethylene glycol	Plasticizer
Talc	Anti-tacking and coating aid
Titanium dioxide and colorants	Appearance and strength identification

Hypromellose is the critical excipient in the ER platform. Its viscosity grade, substitution pattern, particle size, hydration behavior, and concentration can materially affect release. These attributes are more commercially significant than the coating ingredients.

How does NUCYNTA ER differ from NUCYNTA IR?

Attribute	NUCYNTA IR	NUCYNTA ER
Release objective	Rapid release	Extended release
Primary functional excipient	Croscarmellose sodium	Hypromellose
Main formulation risk	Disintegration and dissolution rate	Matrix hydration, erosion, and dose dumping
Generic development burden	Conventional immediate-release bioequivalence	Complex modified-release equivalence
Key commercial opportunity	Cost, tolerability, tablet size, supply	Release-control engineering and abuse-deterrence
Alcohol interaction concern	Lower formulation complexity	Material risk because of extended-release behavior

NUCYNTA ER is the more defensible formulation target because the release profile depends on matrix behavior, not simply tablet disintegration. A generic version must reproduce the relevant pharmacokinetic profile and demonstrate acceptable dissolution across development conditions.

What excipient strategy is most attractive for NUCYNTA generics?

The best strategy is a conservative excipient platform for IR and a performance-driven matrix platform for ER.

Immediate-release strategy

A generic NUCYNTA IR product can use:

• Lactose-free diluents such as mannitol, dibasic calcium phosphate, or additional microcrystalline cellulose.
• Alternative superdisintegrants such as sodium starch glycolate or crospovidone.
• Copovidone or pregelatinized starch in place of povidone K30.
• Lower-cost or regionally sourced coating systems.
• Direct-compression grades that reduce granulation and drying steps.
• Reduced tablet weight or smaller tablets if dose uniformity and mechanical strength remain acceptable.

The commercial value lies in manufacturing efficiency, global excipient sourcing, and patient-facing differentiation. The technical challenge is maintaining rapid dissolution and consistent tablet performance across strengths.

Extended-release strategy

For NUCYNTA ER, the development focus should be on:

• Hypromellose viscosity and concentration.
• Drug-to-polymer ratio.
• Matrix porosity and tablet hardness.
• Granulation method and water exposure.
• Tablet dimensions and surface-area-to-volume ratio.
• Coating weight and moisture barrier properties.
• Resistance to crushing, powdering, and solvent extraction.

A manufacturer may evaluate polyethylene oxide, high-viscosity hypromellose, ethylcellulose combinations, or other matrix-forming systems. Such substitutions create development flexibility but also increase regulatory risk because changes can affect alcohol-induced release, food effects, dose proportionality, and in vitro-in vivo correlation.

Can excipients create an abuse-deterrent NUCYNTA product?

Excipients can support abuse-deterrent performance, but they do not independently establish abuse-deterrent labeling.

FDA evaluates abuse-deterrent formulations under a product-specific framework. Relevant technologies can include matrices that resist crushing, gelling systems that limit extraction, high-viscosity polymers, and combinations that reduce rapid release when tablets are manipulated.[4]

For NUCYNTA ER, a commercial reformulation could target:

1. Crush resistance.
2. Reduced powder formation.
3. Limited opioid extraction in common solvents.
4. Reduced release after exposure to alcohol.
5. Lower release after chewing or mechanical disruption.

The regulatory burden is substantial. The sponsor would need laboratory manipulation studies, comparative dissolution testing, pharmacokinetic studies, and clinical abuse-potential evidence where required. A reformulation also risks changing the pharmacokinetic profile enough to become a new product rather than a simple generic substitution.

What formulations are commercially attractive for NUCYNTA?

The most practical opportunities are summarized below.

Opportunity	Commercial rationale	Development difficulty
Lactose-free NUCYNTA IR	Supports excipient-sensitive positioning	Low to moderate
Smaller IR tablet	Improves swallowing and logistics	Moderate
Orally disintegrating tapentadol	Potential adherence benefit	High; opioid exposure and taste issues
Abuse-deterrent ER tablet	Differentiation and potential premium pricing	High
Lower-cost ER generic	Broad payer and tender opportunity	Moderate to high
Dose-specific packaging	Supports opioid stewardship and compliance	Low
Moisture-protective blister	Improves stability and unit-dose control	Low
Sprinkle or multiparticulate ER product	Swallowing benefit	High; release-control complexity
Pediatric formulation	Limited by opioid safety and regulatory constraints	Very high

A conventional generic is likely to reach the market faster than a new abuse-deterrent or multiparticulate formulation. The latter products may command stronger differentiation but require a larger clinical and regulatory program.

What is the FDA regulatory status of NUCYNTA?

NUCYNTA is an FDA-approved tapentadol product. NUCYNTA IR is approved for acute pain severe enough to require an opioid analgesic when alternatives are inadequate. NUCYNTA ER is approved for severe and persistent pain requiring an extended opioid treatment strategy, including certain chronic pain settings.[1][2]

Tapentadol products are controlled substances. The labeling contains opioid-class warnings, including risks associated with addiction, abuse, misuse, respiratory depression, accidental ingestion, and interactions with central nervous system depressants.[1][2]

The regulatory pathway depends on the commercial objective:

Product type	Likely pathway
Conventional IR generic	Abbreviated New Drug Application
Conventional ER generic	Abbreviated New Drug Application with modified-release bioequivalence requirements
New abuse-deterrent ER formulation	505(b)(2) or NDA strategy, depending on the product
New dosage form	505(b)(2) or NDA
New indication	Supplemental NDA or 505(b)(2), depending on reliance and formulation

FDA approval does not automatically confer abuse-deterrent status. The label must reflect the evidence accepted by FDA.

What is the Orange Book status of NUCYNTA?

The FDA Orange Book is the controlling source for listed patents, exclusivity, therapeutic equivalence ratings, and patent certifications for approved NUCYNTA products.[3]

For commercial planning, the relevant questions are:

• Which NUCYNTA NDA products remain listed?
• Which patents are listed against IR and ER products?
• Are listed patents composition, formulation, method-of-use, or other patents?
• What is the latest expiry date for each listed patent?
• Have generic applicants submitted Paragraph IV certifications?
• Has the reference sponsor initiated litigation within the 45-day period?
• Are any settlements recorded in FDA or Federal Trade Commission materials?

Patent analysis must separate NUCYNTA IR from NUCYNTA ER. The ER formulation generally presents the more important formulation-IP question because release-control technology can support patent claims covering polymer selection, drug-to-polymer ratios, dissolution profiles, and manufacturing processes.

Are biosimilar risks relevant to NUCYNTA?

No. NUCYNTA contains the small-molecule active ingredient tapentadol. Biosimilar and interchangeable-biologic pathways do not apply. Competitive entry would occur through generic or 505(b)(2) pathways rather than through a biosimilar application.

Which companies are positioned to challenge NUCYNTA?

Generic opioid competition typically comes from large manufacturers with controlled-substance infrastructure, established DEA registrations, analytical laboratories, and opioid distribution controls. Potential participants include companies active in generic analgesics and controlled-release oral products, but an applicant-specific Paragraph IV assessment requires current Orange Book and court records.

The primary barriers are operational rather than raw-material availability:

• Controlled-substance quotas and registrations.
• Manufacturing and distribution controls.
• Tamper-resistant packaging expectations.
• Opioid REMS obligations.
• Product diversion controls.
• Bioequivalence requirements for ER products.
• Commercial restrictions imposed by wholesalers, payers, and state opioid programs.

A company with an existing tapentadol API supply chain and controlled-substance commercial infrastructure has a meaningful advantage over a formulation developer without opioid operating capabilities.

What patent litigation and settlement issues affect NUCYNTA?

The key legal risks are likely to involve:

• Paragraph IV challenges to listed patents.
• Claims covering extended-release tapentadol formulations.
• Method-of-use claims for chronic pain treatment.
• Patent-term and regulatory exclusivity calculations.
• Settlement terms governing generic launch dates.
• Potential restrictions on authorized generic competition.

Generic applicants must certify under Paragraph IV when they believe a listed patent is invalid, unenforceable, or will not be infringed. The NDA holder can trigger a 30-month stay by filing suit within the statutory period, subject to statutory exceptions and later court developments.[5]

Settlement agreements involving controlled-substance products receive heightened commercial scrutiny because launch timing, supply arrangements, and authorized-generic provisions can materially affect competition. The Federal Trade Commission reviews certain pharmaceutical patent settlements under the MMA reporting framework.[6]

How strong is the NUCYNTA excipient and formulation estate?

The excipient estate is stronger for NUCYNTA ER than for NUCYNTA IR.

Dimension	NUCYNTA IR	NUCYNTA ER
Reliance on common excipients	High	Moderate
Substitution flexibility	High	Limited
Dissolution sensitivity	Moderate	High
Manufacturing complexity	Low to moderate	Moderate to high
Abuse-deterrence opportunity	Limited	Material
Formulation-patent potential	Moderate	Higher
Generic development risk	Moderate	Higher

A patent claim directed only to a named excipient may be vulnerable if the excipient is replaceable without changing the essential product performance. Claims tied to release kinetics, matrix architecture, extraction resistance, or defined dissolution behavior are generally more commercially consequential because they can constrain viable alternatives.

What commercial opportunities exist beyond a conventional generic?

The largest opportunities are in product differentiation rather than excipient resale.

Excipient suppliers

Suppliers can target:

• High-viscosity hypromellose grades with tight lot-to-lot control.
• Direct-compression excipients for IR tapentadol.
• Abuse-deterrent polymer systems.
• Low-moisture excipients for stability-sensitive tablets.
• Film-coating systems optimized for opioid product identification.
• Ready-to-use coating premixes that shorten scale-up.

Finished-dose manufacturers

Manufacturers can pursue:

• Lower-cost IR and ER generics.
• Lactose-free IR products.
• Smaller, easier-to-swallow tablets.
• Unit-dose blister packaging.
• Abuse-deterrent ER products.
• Regional products using qualified local excipient suppliers.
• Authorized-generic or contract-manufacturing arrangements.

Licensing and partnering

The most valuable licensing assets are likely to be:

• Proven ER matrix technology.
• Abuse-deterrent platform data.
• Tapentadol formulation know-how.
• Controlled-substance manufacturing capacity.
• Bioequivalence data packages.
• Patent positions covering non-infringing release profiles.

A licensing deal based only on a replacement excipient is less defensible than one covering a validated formulation, manufacturing process, and regulatory package.

When does NUCYNTA lose exclusivity and what launch scenarios follow?

Exclusivity analysis must distinguish FDA regulatory exclusivity from patent protection. New-drug exclusivity may expire before listed patents, while patents can extend beyond the regulatory exclusivity period. Generic entry can occur after all blocking patents are invalidated, expire, are licensed, or are otherwise removed as a barrier.

The principal launch scenarios are:

Scenario	Market effect
First conventional IR generic	Rapid price erosion and payer substitution
First ER generic	Slower substitution because modified-release evidence is more complex
Authorized generic	Greater price pressure and reduced first-filer economics
505(b)(2) abuse-deterrent product	Potential premium segment with separate clinical positioning
Limited-distribution launch	Controlled availability but lower commercial reach
Multiple generic entrants	Accelerated price compression

NUCYNTA ER is more likely to retain differentiated value if a generic cannot match release performance, supply reliability, or prescriber confidence. NUCYNTA IR is more exposed to conventional generic substitution because its excipient platform is relatively standard.

Key Takeaways

• NUCYNTA IR uses a conventional tablet platform built around microcrystalline cellulose, lactose, croscarmellose sodium, povidone, and magnesium stearate.
• NUCYNTA ER relies on hypromellose matrix technology, making polymer grade and release behavior the central formulation issues.
• The strongest generic opportunity is a reliable, lower-cost ER product supported by robust dissolution and bioequivalence data.
• Lactose-free IR tablets and improved swallowing characteristics offer modest differentiation.
• Abuse-deterrent ER formulations have higher commercial potential but require substantial FDA evidence.
• Biosimilar competition is irrelevant because tapentadol is a small molecule.
• Controlled-substance compliance, opioid distribution controls, and ER bioequivalence are major market-entry barriers.
• Formulation patents tied to release behavior and manipulation resistance are more significant than claims covering easily replaceable excipients.

FAQs About NUCYNTA Excipients and Commercial Strategy

Is NUCYNTA lactose-free?

NUCYNTA immediate-release labeling identifies lactose monohydrate as an inactive ingredient. NUCYNTA ER uses a different excipient platform, and its labeling should be checked separately for strength-specific composition.[1][2]

Can a generic manufacturer replace hypromellose in NUCYNTA ER?

Yes, a generic applicant may develop a different excipient composition, but it must demonstrate equivalent performance under FDA requirements. Replacing hypromellose can materially alter release kinetics, food effects, alcohol interaction, and dose dumping risk.

Does NUCYNTA have an abuse-deterrent formulation?

The existence of an extended-release matrix does not by itself establish abuse-deterrent labeling. FDA requires product-specific evidence before granting abuse-deterrent claims.[4]

Is tapentadol API difficult to source?

The API is commercially available, but tapentadol products require controlled-substance manufacturing, quota planning, security controls, and regulated distribution. Those requirements can be more restrictive than ordinary excipient sourcing.

Which NUCYNTA product has greater formulation-IP value?

NUCYNTA ER generally has greater formulation-IP value because its commercial performance depends on matrix-controlled release. NUCYNTA IR is more readily reproduced using standard tablet excipients and conventional manufacturing processes.

References

1. U.S. Food and Drug Administration. (2023). NUCYNTA (tapentadol hydrochloride) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2023). NUCYNTA ER (tapentadol hydrochloride) extended-release tablets: Prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, legal and regulatory provisions.
6. Federal Trade Commission. (2024). Reports on agreements filed under the Medicare Prescription Drug, Improvement, and Modernization Act.